Fig. 2

KRAS mutation promotes accumulation of transgelin-2 protein. a PDAC cells were collected for western blot analysis (left panel). The transgelin-2 protein level was normalized to actin level (right panel). *p < 0.05 compared with the BxPC-3 group. b SW1990, Capan-1 and Hs 766 T cells were co-transfected with FASN firefly luciferase reporter and renilla luciferase reporter for 24 h. The cells were then treated with 15uM U0126 (U0) for 6 h. The FASN firefly luciferase activity was normalized to the renilla luciferase activity. *p < 0.05 compared with the control (CT) group. c-e. SW1990, Capan-1 and Hs 766 T cells were treated with 25 uM fatostain (FA) for 3 h or 15uM U0126 (U0) for 6 h. Then RNA was purified and analyzed by qPCR. *p < 0.05 compared with the control (CT) group. f-h. SW1990, Capan-1 and Hs 766 T cells were treated with 25 uM fatostain (FA) for 3 h or 15uM U0126 (U0) for 6 h. The cells were then collected for western blot analysis (upper panel). The transgelin-2 protein level was normalized to actin level (lower panel). *p < 0.05 compared with the control (CT) group. i. SW1990, Capan-1, Hs 766 T and BxPc3 cells were treated with CHX for the indicated time points. The cells were then collected for western blot analysis. Transgelin-2 level was normalized by β-tubulin level. The normalized transgelin-2 level was expressed as a percentage of the initial level prior to the addition of CHX. *p < 0.05 compared with the BxPc3 group. j. SW1990 cells were treated with ERK1/2 inhibitor U0126 for 3 h. The cells were then treated with CHX for the indicated time points. The cells were then collected for western blot analysis. Transgelin-2 level was normalized by β-tubulin level. The normalized transgelin-2 level was expressed as a percentage of the initial level prior to the addition of CHX. *p < 0.05 compared with the control group